Trials / Withdrawn
WithdrawnNCT01455922
A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Intarcia Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Phase 3 study to examine treatment with ITCA 650 compared to glimepiride when added to metformin monotherapy in reducing HbA1c in patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ITCA 650 | ITCA 650 is exenatide in DUROS |
| DRUG | glimepiride | glimepiride will be up-titrated to 8 mg/day over first 13 weeks |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2011-10-20
- Last updated
- 2012-12-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01455922. Inclusion in this directory is not an endorsement.